Asia Pacific Cancer Biopsy Market Size, Growth and Forecast 2032

Asia Pacific Cancer Biopsy Market Overview:

The Asia Pacific Cancer Biopsy Market size was valued at USD 2,917.45 MN in 2021 and reached USD 4,124.28 MN in 2025. It is anticipated to reach USD 8,097.12 MN by 2032, growing at a CAGR of 8.52% during the forecast period.

Asia Pacific Cancer Biopsy Market Insights

• Market growth is supported by rising cancer diagnosis volume, broader pathology access, liquid biopsy adoption, molecular profiling demand and expanding oncology infrastructure across major Asia Pacific countries.
• Consumables hold a strong position because biopsy workflows require recurring use of needles, reagents, slides, sample containers, preservation media, cartridges and molecular testing materials.
• Tissue Biopsies remain the leading type because they are widely used for histopathology confirmation, tumor grading, staging and biomarker testing across major cancer indications.
• Hospitals remain the leading end users because complex biopsy procedures, imaging guidance, pathology departments and oncology treatment pathways are concentrated in hospital-based networks.

Market Segment Insights

By product

By product, Consumables held a strong position in 2025 because cancer biopsy testing depends on recurring use of sample collection, preservation, processing and molecular testing materials. Hospitals and Diagnostic Centres require biopsy needles, reagents, slides, stains, sample containers, cartridges, extraction materials and testing consumables across tissue and liquid biopsy workflows. Kits are gaining demand as laboratories standardize biopsy processing, molecular profiling and liquid biopsy testing. Instrument demand is supported by imaging-guided biopsy systems, pathology platforms, automated sample processors, sequencing systems and molecular analyzers. Services remain important because hospitals, laboratories and research institutes rely on outsourced testing, sample logistics, pathology interpretation and genomic analysis.

By type

By type, Tissue Biopsies led the Asia Pacific Cancer Biopsy Market in 2025 because tissue-based diagnosis remains the clinical standard for confirming malignancy, identifying tumor subtype and supporting treatment planning. Tissue biopsies are widely used across Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer, Prostate Cancer and other cancers. Liquid Biopsies are gaining momentum because blood-based testing can support minimally invasive genomic profiling, therapy selection, resistance monitoring and recurrence assessment. Adoption of liquid biopsy is strongest in advanced oncology centers, private hospital networks and molecular diagnostic laboratories. Tissue and liquid biopsies are expected to remain complementary because tissue confirms diagnosis while liquid biopsy improves access to molecular information when tissue is limited or difficult to obtain.

By application

By application, Lung Cancer held a strong position in 2025 because treatment selection increasingly depends on tissue diagnosis and biomarker testing. Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer and Liver Cancer also support strong biopsy demand due to high diagnostic volume and growing use of molecular testing. Cervical Cancer remains important in Asia Pacific because screening and pathology confirmation are central to disease management. Kidney Cancer, Bladder Cancer, Esophagus Cancer and Other Cancers create additional demand for biopsy instruments, kits, consumables and services. Growth across applications will depend on screening coverage, physician referral patterns, molecular testing access, reimbursement and oncology infrastructure expansion.

By end user

By end user, Hospitals held the strongest position in 2025 because they conduct complex biopsy procedures, imaging-guided sampling, surgical biopsies, pathology testing and oncology treatment planning. Hospitals also coordinate multidisciplinary cancer care, which increases biopsy use for diagnosis, staging and therapy selection. Diagnostic Centres are gaining share as private laboratory networks expand histopathology, cytology, immunohistochemistry and molecular oncology testing. Research Institutes support demand through clinical trials, biomarker discovery, translational oncology and validation of liquid biopsy methods. Growth across end users will favor organizations that improve sample quality, turnaround time, molecular testing capacity and integration with oncologist workflows.

Key market drivers

Rising cancer burden and diagnostic demand

Rising cancer burden and diagnostic demand represent a major growth driver for the Asia Pacific Cancer Biopsy Market. Higher cancer diagnosis volumes increase demand for Instrument, Kits, Consumables and Services across hospitals and Diagnostic Centres. Biopsy remains essential for confirming malignancy, identifying tumor type and guiding treatment decisions across Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer, Cervical Cancer and other cancers. WHO reported that the Western Pacific Region recorded close to 6.8 million new cancer cases in 2022 and nearly 3.5 million cancer deaths each year, while the WHO South-East Asia Region estimated 2.37 million new cancer cases and 1.53 million deaths in 2022. This disease burden supports sustained demand for biopsy testing and pathology infrastructure across Asia Pacific.

Precision oncology and biomarker testing

Precision oncology and biomarker testing support market growth as treatment decisions increasingly depend on tumor genetics, receptor status, actionable mutations and companion diagnostics. Tissue and liquid biopsy samples are critical for molecular profiling, immunohistochemistry, next-generation sequencing and targeted therapy selection. Hospitals and Diagnostic Centres are expanding capabilities to support biomarker testing for Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and other cancers.

Guardant Health introduced new Smart Liquid Biopsy applications for Guardant360 Liquid in 2025, expanding biomarker identification and cancer subtyping capabilities to help oncologists identify appropriate treatment plans. This driver will strengthen demand for kits, instruments, molecular testing consumables and diagnostic services.

Liquid biopsy adoption

Liquid biopsy adoption is strengthening the market because blood-based testing can support genomic profiling, therapy selection and treatment monitoring with less invasive sampling. It is especially useful when tissue is insufficient, unsafe to collect or difficult to access. Liquid biopsy also supports repeated testing during disease progression, which is important for advanced cancers.

Lucence announced ASCO 2025 data showing that combined circulating tumor DNA and circulating tumor RNA liquid biopsy improved detection of actionable mutations and fusions in metastatic non-small cell lung cancer. Adoption will expand first in advanced oncology centers, private hospitals and molecular diagnostic laboratories, then broaden as reimbursement and physician familiarity improve.

Expansion of molecular diagnostic services

Expansion of molecular diagnostic services is improving biopsy testing access across Asia Pacific. Private diagnostic networks, hospital laboratories and specialized testing providers are investing in molecular oncology, sample logistics, companion diagnostics and genomic interpretation services. This trend supports demand for Consumables, Kits, Instruments and outsourced Services.

QIAGEN expanded its oncology diagnostics portfolio in 2025 through strategic partnerships for minimal residual disease testing in clinical trials and companion diagnostic development, while Roche’s Foundation Medicine moved in 2026 to strengthen its monitoring portfolio with SAGA Diagnostics’ tumor-informed molecular residual disease platform. These developments reflect broader industry investment in advanced cancer testing infrastructure and monitoring workflows.

Key Trends and Opportunities

Liquid biopsy and noninvasive testing expand

Liquid biopsy and noninvasive testing are becoming major opportunities because they can reduce dependence on invasive tissue collection in selected cases. Blood-based testing supports therapy selection, resistance mutation detection, treatment response tracking and recurrence monitoring. This is valuable in Lung Cancer, Colorectal Cancer, Breast Cancer and Prostate Cancer where repeated molecular testing may be required. Liquid biopsy also creates opportunities for sample collection tubes, extraction kits, sequencing services, bioinformatics and companion diagnostics. Adoption will expand first in advanced cancer centers, private hospitals and specialized laboratories. Broader use will depend on clinical validation, affordability, reimbursement and clinician confidence.

Companion diagnostics gain clinical relevance

Companion diagnostics are gaining clinical relevance as oncology care becomes more biomarker-driven. Drug approvals increasingly rely on tests that identify patients eligible for targeted therapies or immunotherapy combinations. This increases demand for high-quality tissue and liquid biopsy samples across major cancer indications. Hospitals and Diagnostic Centres need validated workflows, standardized kits and reliable instruments to support clinical decisions. Pharmaceutical companies may partner with diagnostic firms to expand access to companion testing in Asia Pacific. The opportunity is strongest in Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer, where biomarker-defined treatment pathways are expanding.

Outsourced biopsy testing services grow

Outsourced biopsy testing services are growing as hospitals and smaller laboratories refer complex genomic or molecular oncology tests to specialized providers. This model helps health systems access advanced testing without immediately investing in expensive instruments, sequencing platforms and bioinformatics teams. Outsourced services also support research institutes, clinical trials and pharmaceutical partnerships. Service providers can differentiate through faster turnaround, quality accreditation, broad test menus and strong sample logistics. Demand will rise as oncology care requires more biomarker data and treatment monitoring. Companies that connect local collection networks with regional or global testing infrastructure will gain stronger market access.

Key Market Challenges

Affordability and reimbursement constraints

Affordability and reimbursement constraints remain key challenges for the Asia Pacific Cancer Biopsy Market. Advanced molecular tests, broad genomic panels and liquid biopsy assays can be expensive for patients and health systems. Public reimbursement coverage varies widely by country and may not fully support newer genomic tests. Private insurance can improve access, but coverage remains uneven across markets. Cost sensitivity can delay adoption of liquid biopsy and comprehensive molecular profiling. Suppliers and laboratories must demonstrate clinical value, cost-effectiveness and treatment relevance to improve adoption.

Laboratory infrastructure gaps

Laboratory infrastructure gaps can slow market expansion across emerging Asia Pacific countries. Many regions still face shortages of trained pathologists, molecular laboratory specialists, sequencing infrastructure and quality-controlled sample logistics. Rural and underserved areas may depend on centralized laboratories, which can increase turnaround time and affect sample quality. Liquid biopsy and companion diagnostics require validated workflows, bioinformatics and quality assurance systems. Smaller laboratories may struggle to invest in advanced instruments and technical staff. Capacity-building, training and public-private partnerships will be important to address this challenge.

Sample quality and workflow standardization

Sample quality and workflow standardization create challenges across tissue and liquid biopsy testing. Poor specimen handling, delayed fixation, insufficient tumor content and inconsistent processing can affect diagnostic accuracy. Liquid biopsy testing also requires careful blood collection, stabilization, storage and transport to preserve circulating tumor DNA or RNA. Workflow variation across hospitals, Diagnostic Centres and countries can reduce confidence in results. Standardized kits, training, accreditation and quality-control systems are essential for reliable testing. Companies that support end-to-end workflows will have an advantage.

Regional Analysis

China

China represents a major opportunity within the Asia Pacific Cancer Biopsy Market due to its large cancer patient base, expanding hospital networks and growing molecular diagnostics sector. Demand is supported by Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer and Breast Cancer diagnosis. Hospitals remain central because complex biopsy procedures and oncology treatment pathways are concentrated in large medical centers. Diagnostic Centres and specialized laboratories are expanding genomic testing, liquid biopsy and companion diagnostic capabilities. Growth will depend on reimbursement, regulatory approvals, domestic test development and access across lower-tier cities. China is expected to remain one of the most important regional demand centers through 2032.

Japan

Japan supports strong demand for cancer biopsy products and services due to advanced oncology infrastructure, aging demographics and mature diagnostic systems. Tissue Biopsies remain central for diagnosis and treatment planning, while Liquid Biopsies are gaining use in precision oncology and advanced cancer monitoring. Hospitals and research institutes support strong demand for biomarker testing, next-generation sequencing and clinical trial-linked diagnostics. Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer and Stomach Cancer remain important applications. Japan’s market growth will depend on reimbursement policy, diagnostic innovation and adoption of minimally invasive testing. It remains a premium market for advanced biopsy technologies.

India

India is an expanding market supported by rising cancer diagnosis volume, private hospital growth, diagnostic chain expansion and increasing physician awareness of molecular oncology. Tissue Biopsies remain dominant because histopathology is essential for cancer confirmation across hospitals and Diagnostic Centres. Liquid Biopsies are growing in large urban centers, especially for Lung Cancer and advanced solid tumors. Cost sensitivity remains a major constraint, but private laboratories and oncology hospitals are increasing access to biomarker testing. Demand for Consumables and Services is expected to rise as biopsy volume expands. India offers long-term growth potential as cancer care infrastructure and diagnostic access improve.

South Korea

South Korea represents a technologically advanced biopsy market supported by strong hospital systems, cancer screening programs, molecular diagnostics and clinical research. Hospitals and research institutes support adoption of biopsy instruments, kits, consumables and advanced testing services. The country has strong demand for Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer and Liver Cancer testing. Liquid biopsy adoption is gaining momentum through precision oncology programs and private diagnostic innovation. Fast clinical adoption of advanced diagnostics supports premium product demand. South Korea will remain an attractive market for molecular biopsy platforms and oncology testing services.

Australia and New Zealand

Australia and New Zealand represent mature markets supported by structured cancer care pathways, strong pathology networks and high clinical awareness. Tissue Biopsies remain central, while Liquid Biopsies are gaining relevance in advanced cancer management and treatment monitoring. Hospitals, Diagnostic Centres and research institutes support strong demand for molecular profiling and companion diagnostics. Breast Cancer, Colorectal Cancer, Prostate Cancer and Lung Cancer are major application areas. Reimbursement and evidence requirements shape adoption of advanced tests. These markets are expected to remain important for premium biopsy technologies and research-linked diagnostic services.

Southeast Asia

Southeast Asia represents a high-potential market with varied diagnostic capacity across Singapore, Thailand, Malaysia, Indonesia, Vietnam and the Philippines. Singapore supports advanced molecular diagnostics and liquid biopsy adoption, while larger emerging markets are expanding pathology and oncology infrastructure. Hospitals remain the leading end users, but Diagnostic Centres are growing through private health care investment. Lung Cancer, Breast Cancer, Colorectal Cancer, Liver Cancer and Cervical Cancer support strong diagnostic demand. Affordability, sample logistics and laboratory capacity remain important constraints. The region offers long-term growth as private diagnostics, insurance coverage and precision oncology adoption expand.

Report Attribute Details

Asia Pacific Cancer Biopsy Market Segmentations

By Product

• Instrument
• Kits
• Consumables
•  Services

By Type

• Tissue Biopsies
• Liquid Biopsies

By Application

• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
•  Kidney Cancer
• Bladder Cancer
• Other Cancers

By End User

• Hospitals
• Diagnostic Centres
• Research Institutes

Key Players

• QIAGEN
•  Illumina, Inc.
•  Thermo Fisher Scientific
• BD
• Biodesix
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Hologic, Inc.
• Oncimmune Holdings PLC
•  F. Hoffmann-La Roche Ltd.
• Guardant Health Inc.
• Epigenomics AG

Recent Developments

• In February 2025, Hologic obtained CE Mark for Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with lesion targeting to support breast biopsy workflows.
• In May 2025, Guardant Health introduced new Smart Liquid Biopsy applications for Guardant360 Liquid, expanding biomarker identification and cancer subtyping capabilities.
• In May 2025, Lucence announced ASCO 2025 data showing that combined ctDNA and ctRNA liquid biopsy improved diagnostic yield in metastatic non-small cell lung cancer.
• In June 2025, QIAGEN expanded its oncology diagnostics portfolio through strategic partnerships focused on minimal residual disease testing in clinical trials and companion diagnostic development.

Report Coverage

The research report offers an in-depth analysis based on product, type, application, end user and geography. It details leading market players, providing an overview of their business positioning, biopsy product portfolios, molecular diagnostic capabilities, laboratory services and strategic relevance in the Asia Pacific Cancer Biopsy Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines cancer diagnosis volume, tissue biopsy use, liquid biopsy adoption, molecular profiling, companion diagnostics and expansion of diagnostic services as major factors shaping market development. The report assesses the impact of affordability, reimbursement, laboratory infrastructure, sample quality and workflow standardization on market growth. It provides strategic recommendations for diagnostic companies, hospitals, Diagnostic Centres, research institutes, laboratory service providers, investors and new entrants seeking to navigate Asia Pacific’s cancer biopsy ecosystem.

Future Outlook

• Demand for cancer biopsy products will continue to rise as Asia Pacific health systems expand cancer diagnosis and precision oncology capabilities.
• Consumables will remain a major product category due to recurring use across tissue processing, sample preparation and molecular testing workflows.
• Kits will gain demand as laboratories standardize tissue and liquid biopsy workflows.
• Tissue Biopsies will remain the leading type because they are essential for diagnosis, histology, grading and biomarker confirmation.
• Liquid Biopsies will grow quickly as blood-based genomic profiling and treatment monitoring gain clinical acceptance.
• Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer and Liver Cancer will remain key application areas.
• Hospitals will remain the leading end users because complex biopsy procedures and oncology treatment pathways are concentrated in hospital networks.
• Diagnostic Centres will gain share as private laboratories expand histopathology, cytology and molecular testing services.
• China, Japan, India, South Korea and Southeast Asia will remain major demand centers.
• Competition will increase as global diagnostics companies compete on test accuracy, sample workflow, laboratory partnerships, service reach and affordability.